To include your compound in the COVID-19 Resource Center, submit it here.

Elan reports third quarter earnings

Third quarter sales of ELN's retained products were up 31% to $119.5 million from $91.1

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE